Circulating microRNAs as potential biomarkers in triple-negative breast cancer: a translational research study of the NACATRINE trial.
Ana Julia Aguiar de FreitasCaroline Rocha NunesMax Senna ManoRhafaela Lima CausinStéphanie CalfaMarco Antonio de OliveiraIara Viana Vidigal SantanaCristiano de Pádua SouzaMárcia Maria Chiquitelli MarquesPublished in: Future oncology (London, England) (2023)
Liquid biopsy is increasingly vital in monitoring neoadjuvant breast cancer treatment. This study collected plasma samples at three time points from participants in the Neoadjuvant Carboplatin in Triple Negative Breast Cancer (NACATRINE), analyzing miRNA expression with NanoString's nCounter ® Human v3 miRNA assay. In the carboplatin arm, four ct-miRNAs exhibited dynamic changes linked to pathologic complete response, with a combined area under the curve of 0.811. Similarly, the non-carboplatin arm featured four ct-miRNAs with an area under the curve of 0.843. These findings underscore the potential of ct-miRNAs as personalized tools in breast cancer treatment, assisting in predicting treatment response and assessing the risk of relapse. Integrating ct-miRNA analysis into clinical practice can optimize decisions and enhance patient outcomes.
Keyphrases
- image quality
- dual energy
- computed tomography
- contrast enhanced
- locally advanced
- rectal cancer
- phase ii study
- clinical practice
- lymph node
- positron emission tomography
- clinical trial
- magnetic resonance imaging
- poor prognosis
- endothelial cells
- randomized controlled trial
- magnetic resonance
- neoadjuvant chemotherapy
- study protocol
- risk assessment
- ionic liquid
- ultrasound guided
- fine needle aspiration